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Limited data are available regarding comparative prognosis after percutaneous coronary intervention 
(PCI) versus deferral of revascularization in patients with intermediate stenosis with abnormal 
fractional flow reserve (FFR) but preserved coronary flow reserve (CFR). From the International 
Collaboration of Comprehensive Physiologic Assessment Registry (NCT03690713), a total of 330 
patients (338 vessels) who had coronary stenosis with FFR ≤ 0.80 but CFR > 2.0 were selected for the 
current analysis. Patient‑level clinical outcome was assessed by major adverse cardiac events (MACE) 
at 5 years, a composite of all‑cause death, target‑vessel myocardial infarction (MI), or target‑vessel 
revascularization. Among the study population, 231 patients (233 vessels) underwent PCI and 99 
patients (105 vessels) were deferred. During 5 years of follow‑up, cumulative incidence of MACE was 
13.0% (31 patients) without significant difference between PCI and deferred groups (12.7% vs. 14.0%, 
adjusted HR 1.301, 95% CI 0.611–2.769, P = 0.495). Multiple sensitivity analyses by propensity score 
matching and inverse probability weighting also showed no significant difference in patient‑level 
MACE and vessel‑specific MI or revascularization. In this hypothesis‑generating study, there was no 
significant difference in clinical outcomes between PCI and deferred groups among patients with 
intermediate stenosis with FFR ≤ 0.80 but CFR > 2.0. Further study is needed to confirm this finding.
Clinical Trial Registration: International Collaboration of Comprehensive Physiologic Assessment 
Registry (NCT03690713; registration date: 10/01/2018).
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Abbreviations
CFR  Coronary flow reserve
CI  Confidence intervals
FFR  Fractional flow reserve
HR  Hazard ratio
MACE  Major adverse cardiac events
MI  Myocardial infarction
PCI  Percutaneous coronary intervention
Coronary physiologic assessment using pressure-derived fractional flow reserve (FFR) has become a standard 
method for identifying functionally significant epicardial coronary artery  stenosis1–3. Based on multiple clinical 
 trials4–6, FFR-guided percutaneous coronary intervention (PCI) for intermediate stenosis has been incorporated 
into current guidelines and clinical  practice1–3. In the FAME II trial, however, 73.0% of medically managed 
patients with intermediate stenosis and abnormal FFR ≤ 0.80 did not experience any adverse outcomes during 
5-year follow-up6. Furthermore, impairment of myocardial perfusion or ischemia is not only determined by 
the extent of epicardial stenosis, but also by the alteration of coronary microvasculature which cannot be fully 
assessed by  FFR7,8. Coronary flow reserve (CFR), defined as maximal coronary blood flow divided by control 
flow at rest, is a physiologic index reflecting myocardial reserve vasodilator  capacity9. Previous studies indicated 
that depressed CFR was strongly associated with functionally significant disease that is prone to cause  ischemia10, 
and preserved CFR was shown to have excellent negative predictive value for excluding high risk coronary artery 
 disease11. Since discordance between FFR and CFR is not uncommon in patients with intermediate stenosis and 
both indices can provide complementary information regarding underlying pathophysiology, the combined 
measurement of coronary flow and pressure has been suggested for a better understanding of the disease and 
appropriate therapeutic decision  making12–15. Furthermore, recent DEFINE-FLOW study showed comparable 
clinical outcome between deferred patients with FFR ≤ 0.80 and CFR ≥ 2.0 and revascularized patients with 
FFR ≤ 0.80 and CFR < 2.016.
Considering that the recent ISCHEMIA trial did not show benefit of invasive strategy compared with initial 
conservative strategy among patients with stable coronary disease and moderate or severe  ischemia17, a clini-
cally relevant question would be whether preserved CFR in patients with intermediate stenosis and abnormal 
FFR could potentially affect patient’s prognosis according to different treatment strategies. In this regard, the 
comparative efficacy between PCI and deferral for lesion with FFR ≤ 0.80 and CFR ≥ 2.0 needs more clarification, 
however, limited data are available regarding comparative prognosis between PCI and deferral strategies in this 
patient population. Therefore, we sought to investigate clinical outcomes after PCI or deferral of revasculariza-
tion among patients with intermediate coronary stenosis with FFR ≤ 0.80 and CFR > 2.0.
Methods
Study design and population. The study population was derived from the International Collaboration 
of Comprehensive Physiologic Assessment Registry (NCT03690713; registration date 10/01/2018), a pooled 
cohort of 3 prospective registries which have been previously  published18–20. Participants of each registry were 
prospectively enrolled from tertiary medical centers in Korea (Seoul National University Hospital, Samsung 
Medical Center, Inje University Ilsan Paik Hospital, Keimyung University Dongsan Medical Center, and Ulsan 
University Hospital), Japan (Tsuchiura Kyodo General Hospital), and Spain (Hospital Clinico San Carlos), 
respectively. All patients underwent clinically-indicated invasive coronary angiography and comprehensive 
physiologic assessments for at least one vessel with intermediate stenosis (40% to 80% of diameter stenosis)18–20. 
The same exclusion criteria were applied to all 3 registries, and patients with hemodynamic instability or left 
ventricular dysfunction (ejection fraction < 30%) and culprit vessels of acute coronary syndrome were excluded. 
Individual patient data were collected using standardized spreadsheets. For all variables included, standardized 
definitions were used.
Among a total of 1,397 patients (1,694 vessels) from the initial pooled cohort, 330 patients (338 vessels) who 
had intermediate stenosis with abnormal FFR ≤ 0.80 but preserved CFR > 2.0 were included in the current study 
(Fig. 1). Study protocols were designed in accord with the Declaration of Helsinki (2013). All patients gave 
informed consent and the study protocol was authorized by Seoul National University Hospital Institutional 
Review Board.
Coronary angiography and physiologic measurements. All coronary angiograms were performed 
using standard techniques and analyzed at local core laboratories in a blinded  fashion18–20. Percent diameter 
stenosis, minimum luminal diameter, reference-vessel size, and lesion length were  measured21. All coronary 
physiologic indices were measured after diagnostic angiograms. After zeroing and equalizing to the aortic pres-
sure, a pressure–temperature sensor guide wire (Abbott Vascular, St. Paul, MN, USA) was positioned at the 
distal segment of the target vessel to measure the physiologic  indices21. Intracoronary nitrate (100 or 200 µg) 
was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a ther-
modilution curve was obtained using 3 injections of room-temperature saline (4 mL each)19,21. Hyperemia was 
induced by intravenous infusion of adenosine (140 µg/kg/min) through a peripheral or central  vein19,21. Hyper-
emic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during 
sustained hyperemia after the pressure curve reached a nadir  point21,22. The hyperemic period was recognized 
by a decreased Pd/Pa pattern and a left shift in the  Tmn21. FFR was calculated as hyperemic Pd/Pa, at the lowest 
average of 3 consecutive beats during maximal  hyperemia21. CFR was calculated as the resting Tmn divided by 
the hyperemic  Tmn13. After measurements were completed, the guide wire was pulled back to the guide catheter, 
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and the presence of a pressure drift was  checked19,21. Invasive physiologic indices were cross-checked and con-
firmed by principal investigators of each registry.
For lesions with abnormal FFR (≤ 0.80), PCI was recommended according to the current  guidelines21. How-
ever, the final decision for PCI was at the discretion of the operator. Current analysis used only pre-PCI physi-
ologic  indices21.
Data collection, follow up, and clinical outcomes. Patient demographics, cardiovascular risk factors, 
and clinical diagnoses were recorded at the time of index procedure. Clinical data were obtained using standard-
ized spreadsheets at outpatient clinic visits or by telephone contact if needed. Median follow-up duration of the 
study population was 1286 days (interquartile range: 733–1693 days). The primary outcome was patient-level 
MACE during 5 years of follow-up, a composite of all-cause death, target-vessel MI, or target-vessel revasculari-
zation. Vessel-level clinical outcome was also assessed by vessel-specific MI or vessel-specific revascularization. 
All clinical outcomes were defined according to the Academic Research Consortium report. All deaths were 
considered cardiac unless an undisputable non-cardiac cause was present. Periprocedural MI was not accounted 
as a clinical event. Target vessel MI was defined as spontaneous MI which occurred in the initially interrogated 
vessel. Revascularization was additionally adjudicated as to whether the event occurred in the initially inter-
rogated vessel.
Statistical analysis. Analyses were performed on a per-patient basis for clinical characteristics and pri-
mary outcome (and its individual components) and on a per-vessel basis for vessel-related parameters and ves-
sel-level clinical outcomes. If a patient underwent multivessel assessments, the vessel with the lowest FFR value 
was selected as a representative vessel of that patient for per-patient analysis.
Categorical variables were presented as number with relative frequency (percentage) and continuous variables 
as mean with standard deviation or medians with first and third quartiles (Q1-Q3) according to their distribu-
tions determined by Kolmogorov–Smirnov test. The cumulative incidence of clinical events was presented as 
Kaplan–Meier estimate and compared using a log-rank test. Univariable and multivariable Cox proportional 
hazard regressions were used to calculate unadjusted and adjusted HR and 95% CI. Adjusted variables included 
age, gender, diabetes mellitus, hypertension, hypercholesterolemia, current smoking, and presentation with 
acute coronary syndrome. The assumption of proportionality was assessed graphically by log-minus-log plot, 
and Cox proportional hazard models for all clinical outcomes satisfied the proportional hazards assumption.
To further adjust for uneven distribution of baseline characteristics between the PCI and deferred groups, 
multiple sensitivity analyses were performed. First, PS-adjusted Cox proportional hazard regression analyses were 
performed. PS was calculated from multiple logistic regression models after adjusting for age, sex, hypertension, 
diabetes, hypercholesterolemia, smoking, presentation with acute coronary syndrome, target vessel location, 
pre-PCI %DS, lesion length, FFR and CFR. Second, the analyses were repeated in a PS-matched cohort. Third, 
IPW Cox proportional hazard regression models were used.
Figure 1.  Study flow. From the international cohort of 3 prospective registries, 330 patients (338 vessels) with 
abnormal FFR ≤ 0.80 but preserved CFR > 2.0 were included in the current study. CFR Coronary flow reserve, 
FFR Fractional flow reserve, PCI Percutaneous coronary intervention.
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To identify independent predictors of MACE and a composite of vessel-specific MI or revascularization, 
multivariable Cox proportional hazard regression model was constructed using all clinically relevant variables 
and those with a p-value of < 0.05 from the univariate analyses. In addition, comparison of clinical outcomes 
between the PCI and deferred groups was performed within subgroups, according to age (< 70 and ≥ 70 years), 
sex (female and male), diabetes, hypercholesterolemia, current smoking, %DS (> 70% and ≤ 70%), pre-PCI 
FFR (> 0.75 and ≤ 0.75), and pre-PCI CFR (≥ 4.0 and < 4.0). The interaction between treatment effect and these 
covariates was assessed using a Cox proportional hazard regression. All probability values were 2-sided, and 
p-values < 0.05 were considered statistically significant.
Results
Characteristics of the study population. Baseline characteristics of the study population are shown in 
Table 1. The mean age was 64.3 ± 9.7 years and 11.2% were female. Mean percent diameter stenosis (%DS) was 
53.8 ± 13.6, and pre-PCI FFR and CFR were 0.75 (Q1-Q3: 0.71–0.78) and 3.0 (Q1-Q3: 2.5–3.8), respectively. Dis-
tributions of FFR, CFR, and %DS are presented in Supplementary Fig. 1. There was modest correlation between 
pre-PCI FFR and pre-PCI CFR (r = 0.158, P = 0.004) (Fig. 2).
Among the study population, PCI was performed in 231 patients (70.0%) and was deferred in 99 patients 
(30.0%). There was no significant difference in cardiovascular risk factors between PCI and deferred groups 
(Table 1). Compared with deferred vessels, the revascularized vessels showed higher %DS (56.7 ± 13.0 vs. 
47.7 ± 12.8, P < 0.001), longer lesion length (13.24 [Q1-Q3: 8.55–20.35] vs. 10.00 [Q1-Q3: 6.16–18.06], P = 0.026), 
and lower pre-PCI FFR (0.74 [Q1-Q3: 0.69–0.77] vs. 0.78 [Q1-Q3: 0.75–0.79], P < 0.001). Proportions of the ves-
sels with pre-PCI FFR of 0.76–0.80, 0.71–0.75, and ≤ 0.70 were 48.8%, 28.1%, and 23.1%, respectively (Deferred 
group: 72.4%, 21.0%, and 6.7%, respectively; PCI group: 38.2%, 31.3%, and 30.5%, respectively).
Among patients in whom revascularization was deferred, PCI was deferred based on operator’s discretion 
and specific reasons are presented in Table 2. In the deferred group, there was no significant difference in demo-
graphics, cardiovascular risk factors, coronary angiographic findings, and invasive physiologic indices between 
the patients with and without major adverse cardiac events (MACE; Supplementary Table 1).
Clinical outcomes between PCI and deferred groups. During 5 years of follow-up, cumulative inci-
dence of patient-level MACE among the total population was 13.0% (31 patients). There was no significant 
Table 1.  Baseline characteristics of patients and lesions. Values are mean ± standard deviations, median 
(interquartile range), or number (%). CAD Coronary artery disease, CFR Coronary flow reserve, FFR 
Fractional flow reserve, PCI Percutaneous coronary intervention.
Total PCI Deferred P value
Per-patient analysis (n = 330) 330 231 99
Demographics
Age 64.3 ± 9.7 65.1 ± 9.7 62.3 ± 9.3 0.016
Female 37 (11.2) 25 (10.8) 12 (12.1) 0.879
Cardiovascular risk factors
Hypertension 220 (66.7) 151 (65.4) 69 (69.7) 0.524
Diabetes mellitus 109 (33.0) 81 (35.1) 28 (28.3) 0.283
Hyperlipidemia 225 (68.2) 157 (68.0) 68 (68.7) 1.000
Current smoker 74 (22.4) 51 (22.1) 23 (23.2) 0.931
Family history of CAD 30 (9.9) 21 (10.1) 9 (9.5) 1.000
Clinical presentation 0.297
Acute coronary syndrome 39 (11.8) 24 (10.4) 15 (15.2)
Stable ischemic heart disease 291 (88.2) 207 (89.6) 84 (84.9)
Per-vessel analysis (n = 338) 338 233 105
Target vessel location 0.014
Left anterior descending artery 274 (81.3) 182 (78.1) 92 (88.5)
Left circumflex artery 20 (5.9) 13 (5.6) 7 (6.7)
Right coronary artery 43 (12.8) 38 (16.3) 5 (4.8)
Quantitative coronary angiography
Reference vessel diameter, mm 2.77 (2.38–3.15) 2.75 (2.37–3.13) 2.88 (2.38–3.19) 0.597
Minimal luminal diameter, mm 1.26 (1.01–1.56) 1.17 (0.94–1.43) 1.48 (1.17–1.71)  < 0.001
Diameter stenosis, % 53.8 ± 13.6 56.7 ± 13.0 47.7 ± 12.8  < 0.001
Lesion length, mm 12.56 (8.00–19.68) 13.24 (8.55–20.35) 10.00 (6.16–18.06) 0.026
Invasive physiologic indices
FFR, Pre-PCI 0.75 (0.71–0.78) 0.74 (0.69–0.77) 0.78 (0.75–0.79)  < 0.001
CFR, Pre-PCI 3.00 (2.50–3.80) 2.96 (2.50–3.54) 3.14 (2.58–3.90) 0.065
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difference in MACE between PCI and deferred groups (12.7% vs. 14.0%, adjusted hazard ratio [HR] 1.301, 95% 
confidence interval [CI] 0.611–2.769, P = 0.495). Furthermore, the risks of individual components of MACE 
were similar between the 2 groups, including all-cause death, target-vessel myocardial infarction (MI), and 
target-vessel revascularization (Table  3 and Fig.  3). Multiple sensitivity analyses using propensity score (PS) 
adjustment, inverse probability weighted (IPW) adjustment, and PS matched analysis also showed no significant 
difference in the risk of MACE or its individual components between the 2 groups (Table 4).
Similar results were observed in per-vessel analysis. There was no significant difference in vessel-level clinical 
outcomes between PCI and deferred groups with regard to a composite of vessel-specific MI or revascularization 
Figure 2.  Association between FFR and CFR. The association between FFR and CFR among patients with 
FFR ≤ 0.80 and CFR > 2.0 is shown. CFR Coronary flow reserve, FFR Fractional flow reserve.
Table 2.  Specific reasons for deferral of revascularization in patients with FFR ≤ 0.80 and CFR > 2.0. Values 
are proportion (patient number). CFR Coronary flow reserve, FFR Fractional flow reserve, PCI Percutaneous 
coronary intervention.
Reasons for deferral of revascularization Proportion in deferral group
Minimal stenosis on angiography 32.3% (32)
Good exercise performance with tolerable symptom and negative non-invasive tests 17.2% (17)
Diffuse disease without focal stenosis in FFR pullback curve 15.2% (15)
Gray zone FFR with preserved CFR 15.2% (15)
Not suitable for PCI based on clinical condition or technical reason 9.1% (9)
No angiographic progression since previous angiography 8.1% (8)
Small myocardial territory or limited viability 3.0% (3)
Table 3.  Comparison of clinical outcomes according to treatment strategy. Data expressed as cumulative 
incidence of clinical outcomes and number of events. Cumulative incidence of clinical outcomes represents 
Kaplan–Meier estimates during median follow-up of 1286.0 days (Q1-Q3 733.0–1693.0 days). P values for 
log-rank test in survival analysis. *Adjusted for age, sex, diabetes mellitus, hypertension, hypercholesterolemia, 
current smoking, and acute coronary syndrome. † MACE included all-cause death, target-vessel MI, and target-
vessel revascularization. CI Confidence interval, HR Hazard ratio, MACE Major adverse cardiac events, MI 
Myocardial infarction, PCI Percutaneous coronary intervention.
Per-patient analysis PCI (N = 231) Deferred (N = 99)
Unadjusted HR (95% 
CI) P value Adjusted HR* (95% CI) P value
MACE† 12.7 (20) 14.0 (11) 1.156 (0.553–2.419) 0.700 1.301 (0.611–2.769) 0.495
All-cause death 4.8 (7) 6.0 (5) 1.561 (0.494–4.928) 0.448 2.250 (0.653–7.749) 0.199
Target-vessel MI 1.7 (2) 1.3 (1) 0.985 (0.088–11.03) 0.990 0.654 (0.051–8.389) 0.744
Target-vessel revascu-
larization 7.0 (12) 8.5 (6) 1.056 (0.395–2.823) 0.913 1.089 (0.399–2.975) 0.867
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(8.1% vs. 8.0%, adjusted HR 0.932, 95% CI 0.321–2.712, P = 0.898) (Supplementary Table 2 and Supplementary 
Fig. 2). Sensitivity analyses using PS adjustment, IPW adjustment, and PS matching also showed consistent 
results (Supplementary Table 3).
Subgroup analysis and independent predictors of composite outcomes. The prognostic impact 
of revascularization deferral on clinical outcomes among the various subgroups was investigated. There was no 
significant difference in MACE between PCI and deferred groups across all subgroups without significant inter-
Figure 3.  Comparison of major adverse cardiac events according to treatment strategy. Kaplan–Meier 
curves and cumulative incidence of MACE (and its individual components) were compared according to the 
treatment strategies (PCI or deferral of revascularization). Adjusted HR and 95% CI were calculated based on 
multivariable Cox proportional hazard regression model. Adjusted variables included age, sex, diabetes mellitus, 
hypertension, hypercholesterolemia, current smoking, and presentation with acute coronary syndrome. CI 
Confidence interval, HRadj Adjusted hazard ratio, MACE Major adverse cardiac event, MI Myocardial infarction, 
PCI Percutaneous coronary intervention.
Table 4.  Sensitivity analysis regarding clinical outcomes according to treatment strategy. *Propensity score 
was calculated based on multiple logistic regression model after adjusting for age, sex, hypertension, diabetes, 
hypercholesterolemia, smoking, clinical presentation, vessel location, percent diameter stenosis, lesion length, 
pre-intervention fractional flow reserve, and pre-intervention coronary flow reserve. † MACE included all-
cause death, target-vessel MI, and target-vessel revascularization. CI Confidence interval, HR Hazard ratio, 
IPW Inverse probability weight, MI Myocardial infarction, MACE Major adverse cardiac events, PS Propensity 
score.
Per-patient analysis
PS*-adjusted HR (95% 
CI) P value
IPW adjusted HR (95% 
CI) P value
PS*-matched HR (95% 
CI) P value
MACE† 1.754 (0.717–4.288) 0.218 1.011 (0.448–2.284) 0.979 0.995 (0.402–2.461) 0.990
All-cause death 2.277 (0.523–9.920) 0.273 1.364 (0.380–4.895) 0.634 1.942 (0.354–10.64) 0.445
Target-vessel MI 0.445 (0.032–6.190) 0.546 1.505 (0.094–23.98) 0.772 0.799 (0.048–13.22) 0.876
Target-vessel revascu-
larization 1.893 (0.606–5.914) 0.273 0.958 (0.325–2.831) 0.939 0.908 (0.291–2.833) 0.868
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action (Fig. 4). Similarly, there was no difference in vessel-specific MI or revascularization between the 2 groups 
across all subgroups without significant interaction (Supplementary Fig. 3).
In multivariable Cox proportional hazard models, treatment strategy (PCI or deferral) was not independently 
associated with either MACE (adjusted HR 0.463, 95% CI 0.187–1.144, P = 0.095) or a composite of vessel-specific 
MI or revascularization (HR 0.807, 95% CI 0.161–4.045, P = 0.795) (Supplementary Tables 4 and 5).
Discussion
In the current study, we investigated clinical outcomes after PCI or deferral of revascularization among patients 
with intermediate coronary stenosis and abnormal FFR (≤ 0.80) but preserved CFR (> 2.0). The main findings 
were as follows. First, there was no significant difference in MACE and its individual components between PCI 
and deferred groups. These results were consistently observed in multiple sensitivity analyses. Second, per-vessel 
analysis also showed no significant difference in vessel-specific MI or revascularization between the 2 groups. 
Third, similar risk of MACE or vessel-specific MI or revascularization was observed in various subgroups. Fur-
thermore, treatment strategy (PCI or deferral) was not independently associated with either MACE or vessel-
specific MI or revascularization.
FFR has been used as a standard method to identify functionally significant epicardial coronary stenosis with 
the potential to induce myocardial  ischemia1–3, and FFR-guided PCI strategy has been validated by multiple land-
mark clinical  trials4–6. In FAME 2 trial, PCI plus medical therapy was superior to medical therapy alone among 
patients with stable coronary artery disease and functionally significant stenoses determined by FFR ≤ 0.806. In 
this study, however, it should be noted that 73.0% of medically managed patients with functionally significant 
intermediate stenosis had not experienced any adverse outcomes during 5-year follow-up without  PCI6.
This raised an important question regarding how to improve contemporary FFR-guided PCI strategy, which 
requires a thorough understanding of the physiologic basis. In this regard, it is important to recognize that FFR 
is a pressure-derived surrogate of relative flow  reserve23, but not a direct measurement of coronary flow impair-
ment which is a major determinant of myocardial  ischemia12. Also, myocardial contractile function depends on 
coronary flow but not on coronary perfusion  pressure12,14,24. In fact, coronary flow can be low despite normal 
coronary pressure, and vice  versa14,25. Therefore, comprehensive interpretation of both pressure- and flow-based 
indexes would be important for a full physiological evaluation of the target vessel  territories25.
CFR is a well-validated, flow-based physiologic index which permits a comprehensive assessment of the 
coronary  circulation12,14. Disagreement between flow-based CFR and pressure-based FFR has been described 
in up to 40% of  lesions12–15,26, which reflects underlying physiology including atherosclerotic disease pattern, 
Figure 4.  Subgroup analysis for major adverse cardiac events. Comparison of major adverse cardiac event 
according to treatment strategy (PCI or deferral of revascularization) was performed within various subgroups. 
Adjusted HR and 95% CI were calculated based on multivariable Cox proportional hazard regression model. 
Adjusted variables included age, sex, diabetes, hypercholesterolemia, current smoking, and presentation with 
acute coronary syndrome, as appropriate. CFR Coronary flow reserve, CI Confidence interval, DM Diabetes 
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individual susceptibility of flow regulation, and microvascular function. Furthermore, studies have demonstrated 
the impact of a disagreement between FFR and CFR on prognosis. Among patients with deferred lesions with 
preserved FFR, low CFR was associated with a significantly higher risk of adverse outcomes compared with 
preserved  CFR13,15,19,27. Conversely, patients with deferred lesions with low FFR but preserved CFR showed 
similar clinical outcomes compared to those with concordantly preserved  values19,27. These results support that 
coronary flow, which can be represented by CFR, would be a complementary tool to FFR-guided strategy, not 
only to enhance understanding of the disease but also to guide treatment decision-making. However, relatively 
large impact of hemodynamic status on CFR and high measurement variability has been major hurdles in using 
CFR in daily  practice28.
Within this context, a clinically relevant question pertains to what the optimal treatment strategy for interme-
diate stenoses with discordant FFR and CFR values would be. However, little is known regarding the prognosis 
after initial PCI or deferral of revascularization among patients with intermediate stenosis with abnormal FFR 
but preserved CFR. The current study demonstrated that there was no significant difference in clinical outcomes 
according to the initial treatment strategies among those patients. This result is in line with prior studies which 
showed similar prognosis of deferred lesions with FFR ≤ 0.80 but preserved CFR compared to those with concord-
antly preserved  values19,27. Recently, DEFINE-FLOW study (NCT02328820) evaluated comparative prognosis of 
patients according to FFR and CFR. In this study, only patients with FFR ≤ 0.80 and CFR ≤ 2.0 were revascular-
ized, conversely, patients with FFR ≤ 0.80 and CFR > 2.0 were deferred. At 2 years from index procedure, MACE 
rates were comparable between deferred patients with FFR ≤ 0.80 and CFR > 2.0 and revascularized patients with 
FFR ≤ 0.80 and CFR ≤ 2.0 (10.8% vs. 14.4%, respectively)16. These findings suggest possible role of comprehensive 
physiologic assessment. From a hemodynamics perspective, a large pressure drop across an epicardial stenosis 
could be due to an unimpaired coronary vasodilator response resulting in a large trans-stenotic flow-induced 
pressure  gradient14. In such cases, initial revascularization of the epicardial stenosis may not always provide 
significant benefits in increasing coronary flow in subtended myocardial territory. However, it should be noted 
that patients with FFR < 0.75 showed non-significant trend favoring PCI over medical treatment. Considering 
the continuous relationship of FFR with the potential risk of clinical  events29,30, the prognostic impact of PCI 
according to CFR values in patients with FFR ≤ 0.80 might be different according to the ranges of FFR value. In 
DEFINE-FLOW, all patients with FFR ≤ 0.80 and CFR > 2.0 were managed medically and no one underwent PCI 
according to study protocol. Therefore, the current study, where initial deferral strategy was compared with PCI 
among the patients with FFR ≤ 0.80 and CFR > 2.0, was different from DEFINE-FLOW and added unique values 
to the clinically important questions. Both studies are hypothesis-generating and further randomized trials will 
be required due to inherent limitations.
When interpreting the results of the current study, it is important to acknowledge reasons for deferral of 
revascularization determined by individual operators. Common reasons included minimal stenosis on angiog-
raphy (32.3%), good exercise performance with tolerable symptoms and negative non-invasive tests (17.2%), 
and diffuse disease without focal stenosis in FFR pullback curve (15.2%). Also, 15.2% of the deferred cases were 
due to gray zone FFR (0.75–0.80) with preserved CFR, and 76.8% of patients in the deferred group showed 
gray zone FFR. Prior study from IRIS-FFR registry reported that there was no significant difference in clinical 
outcomes between initial revascularization and deferral strategies for coronary stenosis with gray zone  FFR31. In 
their study, higher risk of periprocedural MI after PCI was offset by higher risk of target vessel revascularization 
with deferral among the lesions with gray zone  FFR31. In the current study, 56.1% of the total population and 
76.8% of the patients in the deferred group had gray zone FFR. In contrast to the study from IRIS-FFR registry, 
however, the risk of target vessel revascularization was not significantly higher in the deferred group than the 
PCI group. These results suggest an additional value of CFR in the risk stratification of patients with gray zone 
FFR in whom the decision for revascularization could be individualized without an increased risk of target vessel 
revascularization after deferral.
With the recent ISCHEMIA trial, which did not show benefit of initial invasive strategy compared with initial 
conservative strategy among patients with stable coronary disease and moderate or severe  ischemia17, selecting 
more appropriate candidates for PCI has become an important and challenging question in daily practice. To 
date, well-validated FFR-guided strategy remains as a standard approach to manage patients with intermediate 
coronary stenosis and current guidelines recommend revascularization for patients with FFR ≤ 0.801,2. However, 
it should be noted that FFR is a pressure-derived surrogate of coronary flow and the current results suggest that 
CFR can be used to assist and potentially improve the FFR-guided strategy by providing further information to 
select patients who are able to be medically managed despite abnormal FFR value. These results re-emphasize 
the importance of comprehensive physiologic assessment with combined measurement of coronary pressure 
and flow, and an individualized approach for decision of revascularization. However, the current study should 
be regarded as a hypothesis-generating study due to the limitations as described below.
Some limitations of the current study should be noted. First, since the decision to perform or defer PCI was 
at the discretion of the operator, there is the possibility of selection bias. Second, the inherent limitations of non-
randomized comparisons, such as allocation bias and uneven distribution of risk factors, should be considered. 
In addition, there were significant differences in lesion length, diameter stenosis, and FFR in the target vessels. 
Although multiple sensitivity analyses were performed to adjust for baseline differences and showed similar 
results, unmeasured variables and other potential confounders could not be completely controlled. Third, most 
patients in the deferred group had gray zone FFR values (0.75–0.80) and thus generalization of the results to 
the patients with extremely low FFR and preserved CFR would be limited. Fourth, it is well known that one of 
the most important treatment effects of PCI is relief of symptoms. Since the current registry did not systemati-
cally collect the data on patients’ symptoms after PCI or deferral, this could not be evaluated. Further study is 
required to clarify this issue. Fifth, there was no detailed information on the medication profiles of enrolled 
patients during the follow-up period. Sixth, the number of cases and events, especially in the deferred group, 
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was not enough for comprehensive statistical analysis, although the study population was derived from the large 
international registry.
In conclusion, the current hypothesis-generating study showed that there was no significant difference in 
clinical outcomes following an operator-based decision on PCI between the revascularization and deferred 
groups among patients with intermediate stenosis with FFR ≤ 0.80 but CFR > 2.0. However, there was statistically 
non-significant trend of favoring PCI in patients with FFR < 0.75. Further well-designed study is warranted to 
confirm this finding.
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